Not Hype — the Profit Model Is Changing
On 18 August 2026 Reuters described nicotine pouches as a significant bet by the big tobacco companies on a future beyond cigarettes. That judgement drew attention not just because volumes are climbing, but because the category hits three variables at once: no combustion, easy use, and higher unit profit.
BAT expects global nicotine pouch industry revenue to rise from about £4 billion in 2025 to about £11 billion in 2030. In the first half of 2026 its pouch volumes in Asia, the Middle East and Africa grew 27.5% year on year, to roughly 700 million pouches. PMI has previously disclosed that in 2024 its US oral nicotine business produced gross profit per thousand units at roughly eight times its international cigarette business, with IQOS at roughly 2.4 times.
Sources: Reuters (18 August 2026), BAT public materials, PMI disclosure. The 2030 figure is a company forecast, not an established fact.
For capital markets this stopped being a fringe category some time ago. It is a new growth curve lit up by financial data.
The FDA Opened a Window
What really shifted expectations was the FDA decision of 30 June 2026: twenty ZYN nicotine pouch products, in 3 mg and 6 mg versions, were cleared to carry a specific modified risk claim. The substance of it is that for adults who currently smoke, completely replacing cigarettes with these specific products can lower the associated disease risk.
This is not a safety certification for the category, and it is certainly not an invitation aimed at non-smokers. The orders run for five years, the company must conduct continuing postmarket surveillance, and if youth use rises significantly the FDA can withdraw the authorisation.
From an industry standpoint it is still a clear positive signal: for the first time, nicotine pouches have a harm-reduction communication route that is reproducible and reviewable. Competition shifts away from flavour alone toward scientific evidence, quality consistency and responsible marketing. We take the two FDA authorisations apart in detail here.
The WHO Hit the Brakes — but Regulation Is Not Only Bad News
In May 2026 the World Health Organization published its first global report on nicotine pouches: retail volume above 23 billion pouches in 2024, growth of more than 50% year on year, and a market approaching $7 billion in 2025. At the same time, roughly 160 countries still have no dedicated rules, 16 countries prohibit sale, and 32 countries regulate to varying degrees. The WHO’s emphasis falls on youth-friendly flavours, social media promotion, event sponsorship and high nicotine strengths.
Source: WHO global report on nicotine pouches, May 2026.
These figures look like they cut against the FDA’s. In substance they sketch the same boundary: adult harm reduction is a legitimate discussion, youth protection is not negotiable. For companies genuinely building a long-term business, clearer rules actually help by eliminating the careless operators. Child resistance, seal stability, material selection, dose information presentation and batch traceability move up from packaging details to baseline requirements for market entry.
Growth Will Not Be a Straight Line, but a Pullback Is Not Lost Demand
The curve is volatile. PMI’s ZYN shipments fell 23.5% year on year in the first quarter of 2026, to 2.3 billion pouches — while the company simultaneously cited Nielsen data showing 10% growth in retail offtake, attributing the shipment decline mainly to channel inventory adjustment. By the second quarter, ZYN shipments were up 1.8% year on year at 2.9 billion pouches.
| Period | ZYN shipments | Year on year | Company explanation |
|---|---|---|---|
| Q1 2026 | 2.3bn pouches | −23.5% | Channel inventory adjustment; retail offtake +10% (Nielsen) |
| Q2 2026 | 2.9bn pouches | +1.8% | — |
Inventory, promotion and competition will move quarterly numbers. None of it has changed the direction the majors are taking: keep expanding capacity, keep filling out the strength and flavour matrix.
The bigger test lies outside the US and the Nordics. In markets with no oral nicotine tradition, consumer education takes time, and flavour restrictions, nicotine caps and advertising bans all raise the barrier. But a product that needs no lighting, no device, and produces neither smoke nor vapour can cover occasions cigarettes and vapes cannot reach comfortably. That efficiency is why it will not leave the table easily.
Perhaps Not the Replacement, but the Bridge
So the Reuters read holds up commercially: nicotine pouches are now a key chip for big tobacco in hedging cigarette decline and improving profit structure. Whether the category can carry the future does not depend on a short-term volume spike. It depends on three things — whether it can genuinely absorb complete switching by adult smokers, whether it can keep young people out, and whether it can hold product and supply chain quality under stricter regulation.
It is not a simple stand-in for the cigarette era, and it is not a risk-free “white candy”. The more accurate description is this: in the window while global tobacco moves toward smoke-free, the nicotine pouch is turning from a niche category into infrastructure that will shape where the industry’s next round of capital, brand and manufacturing capability gets allocated. The bet has been placed. What gets tested next is who can make the growth steadier, longer, and more responsible.
